Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
general
A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma
Scientific Reports, Volume 9, No. 1, Article 1322, Year 2019
Notification
URL copied to clipboard!
Description
First-order radiomic features, such as metabolic tumor volume (MTV) and total lesion glycolysis (TLG), are associated with disease progression in early-stage classical Hodgkin lymphoma (HL). We hypothesized that a model incorporating first- and second-order radiomic features would more accurately predict outcome than MTV or TLG alone. We assessed whether radiomic features extracted from baseline PET scans predicted relapsed or refractory disease status in a cohort of 251 patients with stage I-II HL who were managed at a tertiary cancer center. Models were developed and tested using a machine-learning algorithm. Features extracted from mediastinal sites were highly predictive of primary refractory disease. A model incorporating 5 of the most predictive features had an area under the curve (AUC) of 95.2% and total error rate of 1.8%. By comparison, the AUC was 78% for both MTV and TLG and was 65% for maximum standardize uptake value (SUVmax). Furthermore, among the patients with refractory mediastinal disease, our model distinguished those who were successfully salvaged from those who ultimately died of HL. We conclude that our PET radiomic model may improve upfront stratification of early-stage HL patients with mediastinal disease and thus contribute to risk-adapted, individualized management. © 2019, The Author(s).
Authors & Co-Authors
Milgrom, Sarah Allison
United States, Houston
The University of Texas Md Anderson Cancer Center
Elhalawani, Hesham M.
United States, Houston
The University of Texas Md Anderson Cancer Center
Mohamed, Abdallah Sherif Radwan
United States, Houston
The University of Texas Md Anderson Cancer Center
Dabaja, Bouthaina Shbib
United States, Houston
The University of Texas Md Anderson Cancer Center
Pinnix, Chelsea Camille
United States, Houston
The University of Texas Md Anderson Cancer Center
Günther, Jillian R.
United States, Houston
The University of Texas Md Anderson Cancer Center
Court, Laurence Edward
United States, Houston
The University of Texas Md Anderson Cancer Center
Rao, Arvind U.K.
United States, Houston
The University of Texas Md Anderson Cancer Center
Fuller, Clifton David
United States, Houston
The University of Texas Md Anderson Cancer Center
Aristophanous, Michalis
United States, Houston
The University of Texas Md Anderson Cancer Center
Mawlawi, Osama R.
United States, Houston
The University of Texas Md Anderson Cancer Center
Sulman, Erik P.
United States, Houston
The University of Texas Md Anderson Cancer Center
Fanale, Michelle A.
United States, Houston
The University of Texas Md Anderson Cancer Center
Smith, Grace Li
United States, Houston
The University of Texas Md Anderson Cancer Center
Statistics
Citations: 57
Authors: 14
Affiliations: 1
Identifiers
Doi:
10.1038/s41598-018-37197-z
ISSN:
20452322
Research Areas
Cancer
Noncommunicable Diseases
Study Design
Cohort Study